Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...
A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its ...
Please provide your email address to receive an email when new articles are posted on . Use of a precision navigator led to significant increase in genomic profiling among men with prostate cancer.
Inherited CDK12 mutations may mark a rare but aggressive form of prostate cancer, helping identify families who could benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results